Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: A randomized, double-blind, placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 72, Issue 5, 2011, Pages 615-621

  Zhang, Wu Fang ^a   Tan, Yun Long ^b   Zhang, Xiang Yang ^b,d   Chan, Raymond C K ^c   Wu, Hao Ran ^e   Zhou, Dong Feng ^a  

^a PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^b BEIJING HUILONGGUAN HOSPITAL   (China)

^c INSTITUTE OF PSYCHOLOGY   (China)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e Hebei Province Rong Jun Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; GINKGO BILOBA EXTRACT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SULPIRIDE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; ARTICLE; CHINA; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SYSTEMIC DISEASE; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; GINKGO BILOBA; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PHYTOTHERAPY; PLANT EXTRACTS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 79959266946     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05125yel     Document Type: Article

References (50)

1. Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80(1):33-43. doi:10.1016/j.schres.205.07.034 PubMed (Pubitemid 41587461)
2. Caroff SN, Mann SC, Campbell EC, et al. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry. 2002; 63(suppl 4):12-19. PubMed
3. Mauri MC, Regispani F, Beraldo S, et al. Patterns of clinical use of antipsychotics in hospitalized psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(6):957-963. doi:10.1016/j.pnpbp.205.06.09 PubMed (Pubitemid 41080118)
4. Gasquet I, Gury C, Tcherny-Lessenot S, et al. Patterns of prescription of four major antipsychotics: a retrospective study based on medical records of psychiatric inpatients. Pharmacoepidemiol Drug Saf. 2005;14(11): 805-811. doi:10.102/pds.12 PubMed (Pubitemid 41684473)
5. Soares KV, McGrath JJ. The treatment of tardive dyskinesia-a systematic review and meta-analysis. Schizophr Res. 1999;39(1):1-16, discussion 17-18. doi:10.1016/S0920-964(9)021-3 PubMed
6. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull. 1997;23(4):583-609. PubMed
7. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000;61(suppl 4):5-9. PubMed
8. Rotrosen J, Adler L, Lohr J, et al. Antioxidant treatment of tardive dyskinesia. Prostaglandins Leukot Essent Fatty Acids. 1996;55(1-2):77-81. doi:10.1016/S0952-3278(96)90149-0 PubMed (Pubitemid 26321122)
9. Feltner DE, Hertzman M. Progress in the treatment of tardive dyskinesia: theory and practice. Hosp Community Psychiatry. 1993;44(1):25-34. PubMed
10. Cadet JL, Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement disorders: evidence from treatment of tardive dyskinesia with vitamin E. Ann N Y Acad Sci. 1989;570(1):176-185. doi:10.1/j.1749-632.1989.tb14918.x PubMed (Pubitemid 20103394)
11. Lohr JB. Oxygen radicals and neuropsychiatric illness: some speculations. Arch Gen Psychiatry. 1991;48(12):1097-1106. PubMed
12. Lohr JB, Browning JA. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull. 1995;31(1):159-165. PubMed
13. Tsai G, Goff DC, Chang RW, et al. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry. 1998;155(9):1207-1213. PubMed
14. Bishnoi M, Chopra K, Kulkarni SK. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain. Pharmacol Biochem Behav. 2008;88(4): 511-522. doi:10.1016/j.pb.207. 10.09 PubMed (Pubitemid 350266795)
15. Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry. 1999;56(9):836-841.
16. Barak Y, Swartz M, Shamir E, et al. Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis. Ann Clin Psychiatry. 1998;10(3):101-105. doi:10.3109/10401239809148942 PubMed (Pubitemid 28495143)
17. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry. 2007;68(11):1648-1654. doi:10.408/JCP.v68n103 PubMed (Pubitemid 350247493)
18. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 2001;158(9):1511-1514. doi:10.176/api.ajp.158.9.151 PubMed (Pubitemid 32847255)
19. Libov I, Miodownik C, Bersudsky Y, et al. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007; 68(7):1031-1037. doi:10.408/JCP.v68n0709 PubMed (Pubitemid 47340323)
20. Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry. 2001;58(11):1049-1052. doi:10.101/archpsyc.58.1.1049 PubMed (Pubitemid 33051830)
21. Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry. 1996;57(4): 167-173. PubMed
22. Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2001;(4):CD000209. PubMed
23. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs. 2003;17(1):47-62. doi:10.2165/023210-20317010-04 PubMed (Pubitemid 36044348)
24. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets. 2000;1(1):25-58. doi:10.2174/1389450349380 PubMed
25. Ponto LL, Schultz SK. Ginkgo biloba extract: review of CNS effects. Ann Clin Psychiatry. 2003;15(2):109-119. doi:10.3109/10401230309085676 PubMed (Pubitemid 38101802)
26. Maclennan KM, Darlington CL, Smith PF. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol. 2002;67(3):235-257. doi:10.1016/S0301-082(02)015-1 PubMed (Pubitemid 34880132)
27. Ramassamy C, Christen Y, Clostre F, et al. The Ginkgo biloba extract, EGb761, increases synaptosomal uptake of 5-hydroxytryptamine: in-vitro and ex-vivo studies. J Pharm Pharmacol. 1992;44(11):943-945. PubMed
28. Zhang XY, Zhou DF, Zhang PY, et al. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry. 2001;62(11):878-883. PubMed
29. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 1982;39(4):486-487. PubMed
30. Künkel H. EEG profile of three different extractions of Ginkgo biloba. Neuropsychobiology. 1993;27(1):40-45. doi:10.159/018951 PubMed (Pubitemid 23165778)
31. Kanowski S, Herrmann WM, Stephan K, et al. Proof of efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry. 1996;29(2):47-56. doi:10.105/s-207-97954 PubMed (Pubitemid 26116561)
32. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663-667. PubMed
33. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24(1):1-10. PubMed
34. Lohr JB, Cadet JL, Lohr MA, et al. Alpha-tocopherol in tardive dyskinesia. Lancet. 1987;329(8538):913-914. doi:10.1016/S0140-6736(87)92878-9 (Pubitemid 17050290)
35. Caroff SN, Walker P, Campbell C, et al. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. J Clin Psychiatry. 2007;68(3):410-415. doi:10.408/JCP.v68n0309 PubMed (Pubitemid 46506806)
36. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed
37. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and a crosssectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand suppl. 1987;76(s334):1-100. doi:10.1/j.160-047.1987.tb1056.x (Pubitemid 17115352)
38. MacLeod CM. Half a century of research on the Stroop effect: an integrative review. Psychol Bull. 1991;109(2):163-203. doi:10.1037/03-2909.109. 2.163 PubMed
39. Simpson GM, Lee JH, Zoubok B, et al. A rating scale for tardive dyskinesia. Psychopharmacology (Berl). 1979;64(2):171-179. doi:10.107/BF0496058 PubMed (Pubitemid 9227085)
40. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982;39(7):784-788. PubMed
41. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
42. Christen Y. Ginkgo biloba and neurodegenerative disorders. Front Biosci. 2004;9(1-3):3091-3104. doi:10.2741/1462 PubMed
43. Naik SR, Pilgaonkar VW, Panda VS. Evaluation of antioxidant activity of Ginkgo biloba phytosomes in rat brain. Phytother Res. 2006;20(11): 1013-1016. doi:10.102/ptr.1976 PubMed (Pubitemid 44763790)
44. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L: chemistry, efficacy, safety, and uses. J Food Sci. 2008;73(1):R14-R19. PubMed
45. Ramassamy C, Longpré F, Christen Y. Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence? Curr Alzheimer Res. 2007;4(3): 253-262. doi:10.2174/1567205078107304 PubMed
46. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr. 2000; 71(2):621S-629S. PubMed
47. Vellas B, Andrieu S, Ousset PJ, et al; GuidAge Study Group. The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology. 2006;67(suppl 3):S6-S11. PubMed
48. Tammenmaa IA, Sailas E, McGrath JJ, et al. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(7):1099-1107. doi:10.1016/j.pnpbp.204.05.045 PubMed (Pubitemid 40021767)
49. Zhang XY, Zhou DF, Cao LY, et al. The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl). 2006;188(1):12-17. doi:10.107/s0213-06-0476-2 PubMed (Pubitemid 44268237)
50. Le Bars PL, Velasco FM, Ferguson JM, et al. Influence of the severity of cognitive impairment on the effect of the Ginkgo biloba extract EGb 761 in Alzheimer's disease. Neuropsychobiology. 2002;45(1):19-26. (Pubitemid 34117724)